OncoMatch/Clinical Trials/NCT06418776
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
Is NCT06418776 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for refractory acute myeloid leukemia.
The primary objective is to evaluate the efficacy and toxicity of high versus low intensity therapy options in patients with refractory forms and early relapses of acute myeloid leukemia (R/R AML) who are scheduled for allogeneic hematopoietic stem cell transplantation (alloHSCT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: BCL2 inhibitor (venetoclax)
Previous refractoriness or loss of response during ongoing venetoclax therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Previous alloHSCT
Lab requirements
Kidney function
Chronic kidney disease with GFR ≤ 30 ml/min/1.73 m2 (CKD-EPI Creatinine Equation)
Liver function
Cirrhosis classes B-C (Child-Pugh); Total bilirubin > 1.5x normal; AST, ALT > 10x normal
Cardiac function
Uncontrolled arterial hypertension; stable angina III-IV; unstable angina/myocardial infarction <6 months; heart failure IIb-III, NYHA III-IV; uncontrolled cardiac rhythm disturbances (≥ 2 grade CTCAE 5.0); clinically significant ECG abnormalities
Cirrhosis classes B-C according to the Child-Pugh classification; Total bilirubin > 1.5 above the normal range; AST, ALT > 10 above the normal range; Chronic kidney disease with GFR ≤ 30 ml/min/1.73 m2 (CKD-EPI Creatinine Equation); Severe cardiac pathology: uncontrolled arterial hypertension; stable angina III-IV functional classes; unstable angina and/or myocardial infarction less than 6 months before inclusion in the study; heart failure stages IIb-III, NYHA functional classes III-IV; uncontrolled cardiac rhythm disturbances (≥ 2 grade CTCAE 5.0) or clinically significant ECG abnormalities.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify